Navigation Links
Peregrine Pharmaceuticals Receives Additional Time to Regain Compliance With NASDAQ's Minimum Bid Price Rule
Date:10/23/2008

- Company Now Has Until April 27, 2009 to Regain Compliance with $1.00

Minimum Bid Price Rule -

TUSTIN, Calif., Oct. 23 /PRNewswire-FirstCall/ -- Peregrine Pharmaceuticals, Inc. (Nasdaq: PPHM), a clinical stage biopharmaceutical company developing monoclonal antibodies for the treatment of cancer and serious virus infections, today announced that it has received a letter from NASDAQ that provides Peregrine with additional time to regain compliance with the minimum bid price rule. Peregrine now has until April 27, 2009 to regain compliance with NASDAQ's $1.00 minimum bid price rule in order to remain listed on The Nasdaq Stock Market. This extension was granted as part of NASDAQ's recently announced temporary suspension of the minimum bid price and market value requirements for all NASDAQ-listed companies.

As previously announced, Peregrine received a letter from NASDAQ on September 16, 2008 informing the company that the Nasdaq Listing Qualifications Panel had granted Peregrine's request to remain listed on NASDAQ, subject to the condition that on or before January 20, 2009, Peregrine must have evidenced a closing bid price of $1.00 or more for a minimum of ten prior consecutive trading days. This deadline is now extended until April 27, 2009.

Peregrine also announced that at the company's Annual Meeting of Stockholders held on October 21, 2008, stockholders approved a proposal that provides the company's Board of Directors with discretionary authority over the course of the next year to implement a reverse split of the issued and outstanding shares of Peregrine's common stock as a potential remedy to regain compliance with the $1.00 minimum bid price rule.

About Peregrine Pharmaceuti
'/>"/>

SOURCE Peregrine Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Peregrine Pharmaceuticals Reports Progress in Its Phase II Trial of Bavituximab Plus Docetaxel in Patients With Advanced Breast Cancer
2. Peregrine Pharmaceuticals Completes Patient Enrollment In First Stage of Bavituximab Phase II Lung Cancer Trial
3. Peregrine Pharmaceuticals Reports Financial Results for the First Quarter of Fiscal Year 2009
4. Peregrine Pharmaceuticals to Report First Quarter FY 2009 Financial Results
5. Peregrine Pharmaceuticals Receives Letter from NASDAQ Citing Failure to Regain Compliance with Minimum Bid Price Rule
6. Peregrine Pharmaceuticals Reports Financial Results for Fiscal Year 2008
7. Peregrine Pharmaceuticals Awarded DTRA Contract Worth up to $44.4 Million to Develop Bavituximab for Viral Hemorrhagic Fevers
8. Peregrine Pharmaceuticals Presents Promising Phase I Data at ASCO and Provides Clinical Update on Its Phase II Bavituximab Breast Cancer Study
9. Peregrine Pharmaceuticals Reports Studies Published in Science Highlight Key Role of Phosphatidylserine (PS) in Viral Infections
10. Peregrine Pharmaceuticals Announces Four Upcoming Presentations at the American Association for Cancer Research 2008 Annual Meeting
11. Peregrine Pharmaceuticals Reports Financial Results for the Third Quarter of Fiscal Year 2008
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/20/2014)... the health of your heart, researchers have discovered. , ... standard TENS machine like those designed to relieve labour ... small raised flap at the front of the ear ... stimulation changed the influence of the nervous system on ... drive failing hearts too hard. , Professor Jim Deuchars, ...
(Date:8/19/2014)... One of the major limitations in ... vascular supply. Nutrient and gas transport throughout synthetic ... for successful regeneration and integration into the patient’s ... vascularization and promote angiogenesis in a variety of ... and architecture, and enhancing scaffolds with stem cells. ...
(Date:8/19/2014)... Pa. , Aug. 19, 2014 A ... has been nominated for a Centers for Disease Control ... addressing a major public health concern. ... System, is one of a team of researchers nominated ... Charles C. Shepard Science Award for Data Methods and ...
(Date:8/19/2014)... Jolla, CA (PRWEB) August 19, 2014 ... toll Parkinson’s disease can take on an individual. ... extremities, decreased facial expression, problems swallowing and severe depression. ... to the dying off of dopamine producing neurons of ... themselves from a disease that slowly and progressively gets ...
Breaking Biology Technology:'Tickling' your ear could be good for your heart 2Vascularization in Tissue Engineering Highlighted at 12th New Jersey Symposium on Biomaterials Science 2Geisinger investigator nominated for federal award 2Geisinger investigator nominated for federal award 3As We Mourn Robin Williams’ Passing, His Death Sheds Light on Patients Struggling with Parkinson’s Disease 2As We Mourn Robin Williams’ Passing, His Death Sheds Light on Patients Struggling with Parkinson’s Disease 3
... Corporation (OTCBB:RONE), an emerging business development corporation that is ... companies, today announced it will distribute a special dividend ... stock. Regal One is assisting in the filing of ... and Exchange Commission, wherein these shares may be registered ...
... Alliance released the results of its Oncology National Commercial (ONC) ... report of the study,s findings is available at www.campbellalliance.com ... of the results with its clients by request. ... changes in the oncology market over the past 10 years ...
... 31, 2011 Enox Biopharma, Inc., a leader in ... medical devices, today announced that it has expanded its ... a patent application on novel means of delivering nitric ... well recognized as both an antimicrobial agent which can ...
Cached Biology Technology:Regal One Announces Dividend of Rampart Detection Systems Common Stock 2Oncology National Commercial (ONC) Study Outlines 10 Trends Shaping the Market for Oncology Pharmaceutical and Biotech Products 2Enox Biopharma, Inc. Expands Its Technology to Cover the Wound Care Market 2
(Date:8/19/2014)... systems be used in supermarkets to encourage healthier spending ... to answer that very question by tracking the purchasing ... Stars System to rate the nutritional value of foods ... Brand Lab,s David Just, PhD, and Brian Wansink PhD, ... records of over 150 Hannaford Supermarkets in the Northeastern ...
(Date:8/19/2014)... fish purchased at retail seafood counters in 10 ... can expose consumers to unexpectedly high levels of ... falsely present a fish of the same species, ... dangerous mislabeling offense, according to new research by ... labeling of seafood is essential to allow consumers ...
(Date:8/19/2014)... crocodiles colonised the seas during warm phases and became ... study which establishes a link between marine crocodilian diversity ... of more than 140 million years. , The ... de Lyon, France and formerly from the University of ... Communications ., Today, crocodiles are ,cold-blooded, animals that mainly ...
Breaking Biology News(10 mins):Seafood substitutions can expose consumers to unexpectedly high mercury 2Seafood substitutions can expose consumers to unexpectedly high mercury 3Evolution of marine crocodilians constrained by ocean temperatures 2
... of Colorado-Denver and Health Sciences Center and Stanford University ... respond to DNA damage and other acute stresses, and ... lead to new diagnostic markers and cancer treatments with ... the May 21 advanced online version of the journal ...
... forms could be the answer to one of today's ... future. Using a variety of natural food sources, ... fuels like ethanol and even boost the output of ... week at the 106th General Meeting of the (ASM) ...
... Tregs are a specialized subpopulation of T cells that ... harnessing the therapeutic potential of Tregs -- for example, ... arthritis -- is hampered by problems generating sufficient cells ... T cells, Tregs do not proliferate in vitro when ...
Cached Biology News:Researchers uncover new mechanism of tumor suppressor 2Research highlights how bacteria produce energy 2